Literature DB >> 11099900

The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1).

V Berdoukas1, T Bohane, C Eagle, R Lindeman, K DeSilva, V Tobias, D Painter, I Fraser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11099900     DOI： 10.1016/s0955-3886(00)00092-8

Source DB:  PubMed          Journal:  Transfus Sci        ISSN： 0955-3886


× No keyword cloud information.
  3 in total

Review 1.  Friedreich ataxia-update on pathogenesis and possible therapies.

Authors:  Max Voncken; Panos Ioannou; Martin B Delatycki
Journal:  Neurogenetics       Date:  2003-12-19       Impact factor: 2.660

Review 2.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

3.  Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.

Authors:  Nancy F Olivieri; Amir Sabouhanian; Brenda L Gallie
Journal:  PLoS One       Date:  2019-02-27       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.